Shots:
- KaliVir Immunotherapeuticsreported completion of the first cohort in P-I/Ib (STEALTH-001) study evaluating VET3-TGI as a monotx. and in combination with a checkpoint inhibitor in advanced, unresectable, or metastatic solid tumor pts.
- The Data Safety Committee reviewed initial safety data and approved the progression of VET3-TGI to the next IT and IV dosing cohorts
- VET3-TGI is an oncolytic immunotherapy that directly kills tumor cells and boosts anti-cancer immunity by delivering genes for interleukin-12 and a TGF-beta inhibitor
Ref: Kalivir Immunotherapeutics | Image: Kalivir Immunotherapeutics | Press Release
Related News:- Viridian Therapeutics Releases the Long-Term Durability Data Evaluating Veligrotug in P-III (THRIVE) Study in Active TED
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
